nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosinopril—Hypersensitivity—Teniposide—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Fosinopril—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Fosinopril—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Fosinopril—Flushing—Carmustine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Fosinopril—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Fosinopril—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Fosinopril—Anaemia—Bleomycin—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Fosinopril—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Fosinopril—Asthenia—Teniposide—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Fosinopril—Malaise—Bleomycin—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Fosinopril—Pruritus—Teniposide—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Fosinopril—Arrhythmia—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Fosinopril—Leukopenia—Bleomycin—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Fosinopril—Body temperature increased—Fludarabine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Fosinopril—Cough—Bleomycin—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Fosinopril—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Fosinopril—Diarrhoea—Teniposide—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Fosinopril—Chest pain—Bleomycin—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Fosinopril—Myalgia—Bleomycin—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Fosinopril—Discomfort—Bleomycin—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Fosinopril—Chills—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Fosinopril—Ecchymosis—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Fosinopril—Urine output increased—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Fosinopril—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Fosinopril—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Fosinopril—Confusional state—Bleomycin—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Fosinopril—Vision blurred—Carmustine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Fosinopril—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Fosinopril—Tremor—Carmustine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Fosinopril—Oedema—Bleomycin—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Fosinopril—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Fosinopril—Infection—Bleomycin—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Fosinopril—Anaemia—Carmustine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Fosinopril—Vomiting—Teniposide—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Fosinopril—Agitation—Carmustine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Fosinopril—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Fosinopril—Asthenia—Fludarabine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Fosinopril—Rash—Teniposide—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Fosinopril—Dermatitis—Teniposide—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Fosinopril—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Fosinopril—Headache—Teniposide—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Fosinopril—Pruritus—Fludarabine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Fosinopril—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Fosinopril—Leukopenia—Carmustine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Fosinopril—Anorexia—Bleomycin—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Fosinopril—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Fosinopril—Anaemia—Vincristine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Fosinopril—Agitation—Vincristine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Fosinopril—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Fosinopril—Photosensitivity—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Fosinopril—Polyuria—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Fosinopril—Hypotension—Bleomycin—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Fosinopril—Diarrhoea—Fludarabine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Fosinopril—Hypertension—Carmustine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Fosinopril—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Fosinopril—Nausea—Teniposide—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Fosinopril—Anaemia—Mitoxantrone—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Fosinopril—Vertigo—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Fosinopril—Hepatic failure—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Fosinopril—Leukopenia—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Fosinopril—Myalgia—Carmustine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Fosinopril—Chest pain—Carmustine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Fosinopril—Paraesthesia—Bleomycin—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Fosinopril—Malaise—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Fosinopril—Dyspnoea—Bleomycin—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Fosinopril—Renal failure acute—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Fosinopril—Leukopenia—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Fosinopril—Hypertension—Vincristine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Fosinopril—Confusional state—Carmustine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Fosinopril—Oedema—Carmustine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Fosinopril—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Fosinopril—Decreased appetite—Bleomycin—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Fosinopril—Myalgia—Vincristine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Fosinopril—Cough—Mitoxantrone—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Fosinopril—Infection—Carmustine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Fosinopril—Vomiting—Fludarabine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Fosinopril—Rash—Fludarabine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Fosinopril—Dermatitis—Fludarabine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Fosinopril—Hypertension—Mitoxantrone—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Fosinopril—Pain—Bleomycin—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Fosinopril—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Fosinopril—Headache—Fludarabine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Fosinopril—Tachycardia—Carmustine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Fosinopril—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Fosinopril—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Fosinopril—Chest pain—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Fosinopril—Myalgia—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Fosinopril—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Fosinopril—Discomfort—Mitoxantrone—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Fosinopril—Oedema—Vincristine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Fosinopril—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Fosinopril—Anorexia—Carmustine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Fosinopril—Infection—Vincristine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Fosinopril—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Fosinopril—Confusional state—Mitoxantrone—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Fosinopril—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Fosinopril—Hypotension—Carmustine—lymphatic system cancer	0.001	0.001	CcSEcCtD
Fosinopril—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.001	0.001	CcSEcCtD
Fosinopril—Oedema—Mitoxantrone—lymphatic system cancer	0.001	0.001	CcSEcCtD
Fosinopril—Nausea—Fludarabine—lymphatic system cancer	0.000998	0.000998	CcSEcCtD
Fosinopril—Infection—Mitoxantrone—lymphatic system cancer	0.000993	0.000993	CcSEcCtD
Fosinopril—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000992	0.000992	CcSEcCtD
Fosinopril—Shock—Mitoxantrone—lymphatic system cancer	0.000984	0.000984	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00098	0.00098	CcSEcCtD
Fosinopril—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000979	0.000979	CcSEcCtD
Fosinopril—Urticaria—Bleomycin—lymphatic system cancer	0.000979	0.000979	CcSEcCtD
Fosinopril—Anorexia—Vincristine—lymphatic system cancer	0.000978	0.000978	CcSEcCtD
Fosinopril—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000976	0.000976	CcSEcCtD
Fosinopril—Body temperature increased—Bleomycin—lymphatic system cancer	0.000974	0.000974	CcSEcCtD
Fosinopril—Insomnia—Carmustine—lymphatic system cancer	0.000973	0.000973	CcSEcCtD
Fosinopril—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000966	0.000966	CcSEcCtD
Fosinopril—Paraesthesia—Carmustine—lymphatic system cancer	0.000966	0.000966	CcSEcCtD
Fosinopril—Mood swings—Methotrexate—lymphatic system cancer	0.00096	0.00096	CcSEcCtD
Fosinopril—Hypotension—Vincristine—lymphatic system cancer	0.000959	0.000959	CcSEcCtD
Fosinopril—Dyspnoea—Carmustine—lymphatic system cancer	0.000959	0.000959	CcSEcCtD
Fosinopril—Somnolence—Carmustine—lymphatic system cancer	0.000956	0.000956	CcSEcCtD
Fosinopril—Anorexia—Mitoxantrone—lymphatic system cancer	0.000953	0.000953	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000935	0.000935	CcSEcCtD
Fosinopril—Decreased appetite—Carmustine—lymphatic system cancer	0.000935	0.000935	CcSEcCtD
Fosinopril—Hypotension—Mitoxantrone—lymphatic system cancer	0.000934	0.000934	CcSEcCtD
Fosinopril—Insomnia—Vincristine—lymphatic system cancer	0.000928	0.000928	CcSEcCtD
Fosinopril—Paraesthesia—Vincristine—lymphatic system cancer	0.000922	0.000922	CcSEcCtD
Fosinopril—Constipation—Carmustine—lymphatic system cancer	0.00092	0.00092	CcSEcCtD
Fosinopril—Pain—Carmustine—lymphatic system cancer	0.00092	0.00092	CcSEcCtD
Fosinopril—Breast disorder—Methotrexate—lymphatic system cancer	0.000916	0.000916	CcSEcCtD
Fosinopril—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000913	0.000913	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000911	0.000911	CcSEcCtD
Fosinopril—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000908	0.000908	CcSEcCtD
Fosinopril—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000898	0.000898	CcSEcCtD
Fosinopril—Decreased appetite—Vincristine—lymphatic system cancer	0.000892	0.000892	CcSEcCtD
Fosinopril—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000891	0.000891	CcSEcCtD
Fosinopril—Somnolence—Mitoxantrone—lymphatic system cancer	0.000889	0.000889	CcSEcCtD
Fosinopril—Feeling abnormal—Carmustine—lymphatic system cancer	0.000886	0.000886	CcSEcCtD
Fosinopril—Fatigue—Vincristine—lymphatic system cancer	0.000885	0.000885	CcSEcCtD
Fosinopril—Asthenia—Bleomycin—lymphatic system cancer	0.000884	0.000884	CcSEcCtD
Fosinopril—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00088	0.00088	CcSEcCtD
Fosinopril—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000879	0.000879	CcSEcCtD
Fosinopril—Constipation—Vincristine—lymphatic system cancer	0.000878	0.000878	CcSEcCtD
Fosinopril—Pain—Vincristine—lymphatic system cancer	0.000878	0.000878	CcSEcCtD
Fosinopril—Asthma—Methotrexate—lymphatic system cancer	0.000876	0.000876	CcSEcCtD
Fosinopril—Pruritus—Bleomycin—lymphatic system cancer	0.000872	0.000872	CcSEcCtD
Fosinopril—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000869	0.000869	CcSEcCtD
Fosinopril—Eosinophilia—Methotrexate—lymphatic system cancer	0.000867	0.000867	CcSEcCtD
Fosinopril—Fatigue—Mitoxantrone—lymphatic system cancer	0.000862	0.000862	CcSEcCtD
Fosinopril—Pancreatitis—Methotrexate—lymphatic system cancer	0.000859	0.000859	CcSEcCtD
Fosinopril—Pain—Mitoxantrone—lymphatic system cancer	0.000855	0.000855	CcSEcCtD
Fosinopril—Constipation—Mitoxantrone—lymphatic system cancer	0.000855	0.000855	CcSEcCtD
Fosinopril—Abdominal pain—Carmustine—lymphatic system cancer	0.00085	0.00085	CcSEcCtD
Fosinopril—Body temperature increased—Carmustine—lymphatic system cancer	0.00085	0.00085	CcSEcCtD
Fosinopril—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000839	0.000839	CcSEcCtD
Fosinopril—Pancytopenia—Methotrexate—lymphatic system cancer	0.000832	0.000832	CcSEcCtD
Fosinopril—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000824	0.000824	CcSEcCtD
Fosinopril—Neutropenia—Methotrexate—lymphatic system cancer	0.000819	0.000819	CcSEcCtD
Fosinopril—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000817	0.000817	CcSEcCtD
Fosinopril—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000814	0.000814	CcSEcCtD
Fosinopril—Abdominal pain—Vincristine—lymphatic system cancer	0.000811	0.000811	CcSEcCtD
Fosinopril—Body temperature increased—Vincristine—lymphatic system cancer	0.000811	0.000811	CcSEcCtD
Fosinopril—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000807	0.000807	CcSEcCtD
Fosinopril—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000799	0.000799	CcSEcCtD
Fosinopril—Urticaria—Mitoxantrone—lymphatic system cancer	0.000794	0.000794	CcSEcCtD
Fosinopril—Hypersensitivity—Carmustine—lymphatic system cancer	0.000792	0.000792	CcSEcCtD
Fosinopril—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00079	0.00079	CcSEcCtD
Fosinopril—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00079	0.00079	CcSEcCtD
Fosinopril—Pneumonia—Methotrexate—lymphatic system cancer	0.000785	0.000785	CcSEcCtD
Fosinopril—Vomiting—Bleomycin—lymphatic system cancer	0.000783	0.000783	CcSEcCtD
Fosinopril—Drowsiness—Methotrexate—lymphatic system cancer	0.000781	0.000781	CcSEcCtD
Fosinopril—Rash—Bleomycin—lymphatic system cancer	0.000777	0.000777	CcSEcCtD
Fosinopril—Dermatitis—Bleomycin—lymphatic system cancer	0.000776	0.000776	CcSEcCtD
Fosinopril—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000774	0.000774	CcSEcCtD
Fosinopril—Asthenia—Carmustine—lymphatic system cancer	0.000772	0.000772	CcSEcCtD
Fosinopril—Renal failure—Methotrexate—lymphatic system cancer	0.000768	0.000768	CcSEcCtD
Fosinopril—Hypersensitivity—Vincristine—lymphatic system cancer	0.000756	0.000756	CcSEcCtD
Fosinopril—Epistaxis—Methotrexate—lymphatic system cancer	0.000737	0.000737	CcSEcCtD
Fosinopril—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000737	0.000737	CcSEcCtD
Fosinopril—Asthenia—Vincristine—lymphatic system cancer	0.000736	0.000736	CcSEcCtD
Fosinopril—Diarrhoea—Carmustine—lymphatic system cancer	0.000736	0.000736	CcSEcCtD
Fosinopril—Nausea—Bleomycin—lymphatic system cancer	0.000732	0.000732	CcSEcCtD
Fosinopril—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000729	0.000729	CcSEcCtD
Fosinopril—Asthenia—Mitoxantrone—lymphatic system cancer	0.000717	0.000717	CcSEcCtD
Fosinopril—Dizziness—Carmustine—lymphatic system cancer	0.000711	0.000711	CcSEcCtD
Fosinopril—Haemoglobin—Methotrexate—lymphatic system cancer	0.000705	0.000705	CcSEcCtD
Fosinopril—Diarrhoea—Vincristine—lymphatic system cancer	0.000702	0.000702	CcSEcCtD
Fosinopril—Haemorrhage—Methotrexate—lymphatic system cancer	0.000701	0.000701	CcSEcCtD
Fosinopril—Hepatitis—Methotrexate—lymphatic system cancer	0.000701	0.000701	CcSEcCtD
Fosinopril—Pharyngitis—Methotrexate—lymphatic system cancer	0.000696	0.000696	CcSEcCtD
Fosinopril—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000684	0.000684	CcSEcCtD
Fosinopril—Vomiting—Carmustine—lymphatic system cancer	0.000684	0.000684	CcSEcCtD
Fosinopril—Dizziness—Vincristine—lymphatic system cancer	0.000679	0.000679	CcSEcCtD
Fosinopril—Rash—Carmustine—lymphatic system cancer	0.000678	0.000678	CcSEcCtD
Fosinopril—Dermatitis—Carmustine—lymphatic system cancer	0.000677	0.000677	CcSEcCtD
Fosinopril—Visual impairment—Methotrexate—lymphatic system cancer	0.000676	0.000676	CcSEcCtD
Fosinopril—Headache—Carmustine—lymphatic system cancer	0.000674	0.000674	CcSEcCtD
Fosinopril—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000663	0.000663	CcSEcCtD
Fosinopril—Tinnitus—Methotrexate—lymphatic system cancer	0.000654	0.000654	CcSEcCtD
Fosinopril—Vomiting—Vincristine—lymphatic system cancer	0.000653	0.000653	CcSEcCtD
Fosinopril—Rash—Vincristine—lymphatic system cancer	0.000647	0.000647	CcSEcCtD
Fosinopril—Dermatitis—Vincristine—lymphatic system cancer	0.000647	0.000647	CcSEcCtD
Fosinopril—Headache—Vincristine—lymphatic system cancer	0.000643	0.000643	CcSEcCtD
Fosinopril—Nausea—Carmustine—lymphatic system cancer	0.000639	0.000639	CcSEcCtD
Fosinopril—Vomiting—Mitoxantrone—lymphatic system cancer	0.000636	0.000636	CcSEcCtD
Fosinopril—Rash—Mitoxantrone—lymphatic system cancer	0.00063	0.00063	CcSEcCtD
Fosinopril—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00063	0.00063	CcSEcCtD
Fosinopril—Chills—Methotrexate—lymphatic system cancer	0.000629	0.000629	CcSEcCtD
Fosinopril—Headache—Mitoxantrone—lymphatic system cancer	0.000626	0.000626	CcSEcCtD
Fosinopril—Nausea—Vincristine—lymphatic system cancer	0.00061	0.00061	CcSEcCtD
Fosinopril—Dysgeusia—Methotrexate—lymphatic system cancer	0.000598	0.000598	CcSEcCtD
Fosinopril—Nausea—Mitoxantrone—lymphatic system cancer	0.000594	0.000594	CcSEcCtD
Fosinopril—Vision blurred—Methotrexate—lymphatic system cancer	0.000575	0.000575	CcSEcCtD
Fosinopril—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000566	0.000566	CcSEcCtD
Fosinopril—Anaemia—Methotrexate—lymphatic system cancer	0.000564	0.000564	CcSEcCtD
Fosinopril—Malaise—Methotrexate—lymphatic system cancer	0.00055	0.00055	CcSEcCtD
Fosinopril—Vertigo—Methotrexate—lymphatic system cancer	0.000548	0.000548	CcSEcCtD
Fosinopril—Leukopenia—Methotrexate—lymphatic system cancer	0.000546	0.000546	CcSEcCtD
Fosinopril—Cough—Methotrexate—lymphatic system cancer	0.000533	0.000533	CcSEcCtD
Fosinopril—Myalgia—Methotrexate—lymphatic system cancer	0.00052	0.00052	CcSEcCtD
Fosinopril—Arthralgia—Methotrexate—lymphatic system cancer	0.00052	0.00052	CcSEcCtD
Fosinopril—Chest pain—Methotrexate—lymphatic system cancer	0.00052	0.00052	CcSEcCtD
Fosinopril—Discomfort—Methotrexate—lymphatic system cancer	0.000513	0.000513	CcSEcCtD
Fosinopril—Confusional state—Methotrexate—lymphatic system cancer	0.000502	0.000502	CcSEcCtD
Fosinopril—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000498	0.000498	CcSEcCtD
Fosinopril—Infection—Methotrexate—lymphatic system cancer	0.000495	0.000495	CcSEcCtD
Fosinopril—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000488	0.000488	CcSEcCtD
Fosinopril—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000482	0.000482	CcSEcCtD
Fosinopril—Anorexia—Methotrexate—lymphatic system cancer	0.000475	0.000475	CcSEcCtD
Fosinopril—Hypotension—Methotrexate—lymphatic system cancer	0.000465	0.000465	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000454	0.000454	CcSEcCtD
Fosinopril—Insomnia—Methotrexate—lymphatic system cancer	0.00045	0.00045	CcSEcCtD
Fosinopril—Paraesthesia—Methotrexate—lymphatic system cancer	0.000447	0.000447	CcSEcCtD
Fosinopril—Dyspnoea—Methotrexate—lymphatic system cancer	0.000444	0.000444	CcSEcCtD
Fosinopril—Somnolence—Methotrexate—lymphatic system cancer	0.000443	0.000443	CcSEcCtD
Fosinopril—Dyspepsia—Methotrexate—lymphatic system cancer	0.000438	0.000438	CcSEcCtD
Fosinopril—Decreased appetite—Methotrexate—lymphatic system cancer	0.000433	0.000433	CcSEcCtD
Fosinopril—Fatigue—Methotrexate—lymphatic system cancer	0.000429	0.000429	CcSEcCtD
Fosinopril—Pain—Methotrexate—lymphatic system cancer	0.000426	0.000426	CcSEcCtD
Fosinopril—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00041	0.00041	CcSEcCtD
Fosinopril—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000407	0.000407	CcSEcCtD
Fosinopril—Urticaria—Methotrexate—lymphatic system cancer	0.000396	0.000396	CcSEcCtD
Fosinopril—Abdominal pain—Methotrexate—lymphatic system cancer	0.000394	0.000394	CcSEcCtD
Fosinopril—Body temperature increased—Methotrexate—lymphatic system cancer	0.000394	0.000394	CcSEcCtD
Fosinopril—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000367	0.000367	CcSEcCtD
Fosinopril—Asthenia—Methotrexate—lymphatic system cancer	0.000357	0.000357	CcSEcCtD
Fosinopril—Pruritus—Methotrexate—lymphatic system cancer	0.000352	0.000352	CcSEcCtD
Fosinopril—Diarrhoea—Methotrexate—lymphatic system cancer	0.000341	0.000341	CcSEcCtD
Fosinopril—Dizziness—Methotrexate—lymphatic system cancer	0.000329	0.000329	CcSEcCtD
Fosinopril—Vomiting—Methotrexate—lymphatic system cancer	0.000317	0.000317	CcSEcCtD
Fosinopril—Rash—Methotrexate—lymphatic system cancer	0.000314	0.000314	CcSEcCtD
Fosinopril—Dermatitis—Methotrexate—lymphatic system cancer	0.000314	0.000314	CcSEcCtD
Fosinopril—Headache—Methotrexate—lymphatic system cancer	0.000312	0.000312	CcSEcCtD
Fosinopril—Nausea—Methotrexate—lymphatic system cancer	0.000296	0.000296	CcSEcCtD
